Saturday 17 October 2026
Export ILMN’s income statement to Excel — free account
Illumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue grew 9.44%, EPS fell 8.05%, free cash flow fell 18.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
262.03
5.90
−2.20%
Follow ILMN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
21.25 | 23.93 | 22.29 | 32.50 |
P/S ratio |
3.39 | 4.68 | 4.29 | 5.91 | |
P/FCF ratio |
14.75 | 22.19 | 19.67 | 28.99 | |
P/Operating CF |
51.16 | 63.33 | 65.26 | 132.09 | |
P/B ratio |
6.10 | 7.47 | 7.05 | 9.36 | |
Price to Tangible BV |
13.93 | 14.52 | 19.60 | 23.21 | |
EV/Sales |
3.44 | 4.76 | 4.48 | 6.09 | |
EV/EBITDA |
13.98 | 19.20 | 17.54 | 23.69 | |
EV/Operating CF |
13.13 | 19.16 | 17.45 | 24.99 | |
EV/FCF |
14.96 | 22.57 | 20.52 | 29.87 | |
Quick Ratio |
1.02 | 1.57 | 1.21 | 1.22 | |
Current Ratio |
1.43 | 2.08 | 1.75 | 1.80 | |
Net Debt/EBITDA |
(0.97) | (0.53) | 1.21 | 1.03 | |
Debt/Assets |
16.09% | 22.43% | 22.72% | 22.42% | |
Debt/Equity |
0.42 | 0.55 | 0.56 | 0.53 | |
Asset Turnover |
0.70 | 0.67 | 0.69 | 0.71 | |
Operating CF/Net income |
1.89 | 0.96 | 2.16 | 0.97 | |
Capex/Depreciation |
(0.46) | (0.83) | (0.55) | (0.57) | |
Interest Coverage |
9.08 | 7.77 | 8.71 | 10.21 | |
Research and Development Expense of Revenue |
21.13% | 20.62% | 22.00% | 21.74% | |
Selling, General and Administrative Expense of Revenue |
25.55% | 26.57% | 24.93% | 23.55% | |
Intangible Assets out of Total Assets |
0.22 | 0.20 | 0.26 | 0.25 | |
Share Based Compensation of Revenue |
6.46% | 5.44% | 5.50% | 6.30% | |
Graham Net Nets |
(0.07) | (0.03) | (0.06) | (0.04) | |
Graham Number |
39.56 | 46.54 | 46.65 | 47.83 | |
Earnings Yield |
4.71% | 4.18% | 4.49% | 3.08% | |
Free Cash Flow Yield |
6.78% | 4.51% | 5.09% | 3.45% | |
Revenue per Share |
7.09 | 7.48 | 7.13 | 7.68 | |
Operating CF per Share |
1.86 | 2.07 | 1.89 | 1.33 | |
Capex per Share |
(0.20) | (0.35) | (0.25) | (0.26) | |
Free Cash Flow per Share |
1.65 | 1.72 | 1.64 | 1.07 | |
Cash per Share |
8.35 | 10.54 | 7.55 | 7.74 | |
Shareholders Equity per Share |
15.56 | 17.57 | 17.49 | 18.79 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.56 | 17.57 | 17.49 | 18.79 | |
Free Cash Flow |
253.00 | 266.00 | 251.00 | 161.00 | |
Working Capital |
834.00 | 1,704.00 | 1,172.00 | 1,256.00 | |
Capital Expenditures |
(31.00) | (55.00) | (38.00) | (40.00) | |
Net Current Asset Value |
(1,000.00) | (632.00) | (1,145.00) | (978.00) | |
EV/EBIT |
18.91 | 25.62 | 23.10 | 30.99 | |
Capex to Sales |
0.03 | 0.05 | 0.03 | 0.03 | |
Price to Operating Income |
18.65 | 25.19 | 22.13 | 30.07 | |
| Other line items | |||||
Average Receivables |
714.00 | 794.50 | 718.50 | 732.50 | |
Average Payables |
204.50 | 230.50 | 212.50 | 215.00 | |
Average Inventory |
582.00 | 555.50 | 574.00 | 602.00 | |
Average Assets |
6,095.50 | 6,473.50 | 6,370.50 | 6,368.50 | |
Average Common Equity |
2,253.00 | 2,548.00 | 2,522.00 | 2,548.00 |
Columns are period end dates